Chronic Administration of Anacetrapib Is Associated With Accumulation in Adipose and Slow Elimination
Author:
Affiliation:
1. MRL, Merck & Co., Inc.; Kenilworth New Jersey
Publisher
Wiley
Subject
Pharmacology (medical),Pharmacology
Reference20 articles.
1. Disposition into adipose tissue determines accumulation and elimination kinetics of the cholesteryl ester transfer protein inhibitor anacetrapib in mice.;Hartmann;Drug Metab. Dispos.,2016
2. Anacetrapib, a novel CETP inhibitor: pursuing a new approach to cardiovascular risk reduction;Gutstein;Clin. Pharmacol. Ther,2012
3. Safety of anacetrapib in patients with or at high risk for coronary heart disease.;Cannon;N. Engl. J. Med.,2010
4. Evaluation of lipids, drug concentration, and safety parameters following cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib in patients with or at high risk for coronary heart disease;Gotto;Am. J. Cardiol,2014
5. Impact of lipoproteins on the biological activity and disposition of hydrophobic drugs: implications for drug discovery;Wasan;Nat. Rev. Drug Discov,2008
Cited by 45 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Quantitation of anacetrapib in human and animal adipose by liquid chromatography with mass spectrometric detection;Bioanalysis;2024-08-09
2. Obicetrapib on top of maximally tolerated lipid‐modifying therapies in participants with or at high risk for atherosclerotic cardiovascular disease: rationale and designs of BROADWAY and BROOKLYN;American Heart Journal;2024-08
3. High-Density Lipoprotein Subclasses and Their Role in the Prevention and Treatment of Cardiovascular Disease: A Narrative Review;International Journal of Molecular Sciences;2024-07-18
4. Cholesteryl Ester Transfer Protein Inhibitors and Cardiovascular Outcomes: A Systematic Review and Meta-Analysis;Journal of Cardiovascular Development and Disease;2024-05-16
5. Evolving Therapeutic Targets;Clinical Lipidology;2024
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3